Oruka Therapeutics, Inc. (NASDAQ:ORKA) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA) have received a consensus rating of “Moderate Buy” from the eleven research firms that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating and ten have assigned a buy rating to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $59.60.

A number of equities research analysts have recently commented on ORKA shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Oruka Therapeutics in a report on Thursday, January 22nd. BTIG Research reaffirmed a “buy” rating and set a $73.00 price target on shares of Oruka Therapeutics in a research note on Friday, March 13th. Guggenheim reissued a “buy” rating and set a $60.00 price objective on shares of Oruka Therapeutics in a research note on Friday, March 13th. UBS Group started coverage on Oruka Therapeutics in a research report on Wednesday, January 7th. They issued a “buy” rating and a $50.00 target price on the stock. Finally, Leerink Partners boosted their price target on Oruka Therapeutics from $58.00 to $86.00 and gave the company an “outperform” rating in a research report on Monday, March 16th.

Insiders Place Their Bets

In other Oruka Therapeutics news, insider Joana Goncalves sold 7,641 shares of the business’s stock in a transaction on Monday, March 16th. The shares were sold at an average price of $40.91, for a total value of $312,593.31. Following the transaction, the insider owned 33,377 shares in the company, valued at $1,365,453.07. The trade was a 18.63% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Lawrence Otto Klein sold 1,729 shares of the company’s stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $41.30, for a total transaction of $71,407.70. Following the completion of the transaction, the chief executive officer directly owned 927,309 shares of the company’s stock, valued at approximately $38,297,861.70. The trade was a 0.19% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 23,765 shares of company stock valued at $849,575. 24.69% of the stock is owned by corporate insiders.

Institutional Trading of Oruka Therapeutics

A number of hedge funds have recently made changes to their positions in ORKA. Avoro Capital Advisors LLC bought a new stake in Oruka Therapeutics in the third quarter valued at about $25,640,000. Fairmount Funds Management LLC increased its holdings in shares of Oruka Therapeutics by 9.9% in the 3rd quarter. Fairmount Funds Management LLC now owns 3,705,262 shares of the company’s stock valued at $71,252,000 after acquiring an additional 333,340 shares during the last quarter. Financial Enhancement Group LLC bought a new stake in shares of Oruka Therapeutics in the 3rd quarter valued at approximately $631,000. Empirical Financial Services LLC d.b.a. Empirical Wealth Management bought a new position in Oruka Therapeutics during the third quarter worth $296,000. Finally, B Group Inc. boosted its holdings in Oruka Therapeutics by 28.8% in the second quarter. B Group Inc. now owns 75,000 shares of the company’s stock worth $841,000 after purchasing an additional 16,785 shares during the period. Institutional investors and hedge funds own 56.44% of the company’s stock.

Oruka Therapeutics Trading Up 0.2%

NASDAQ ORKA opened at $38.91 on Friday. The business’s 50 day moving average is $34.24 and its two-hundred day moving average is $28.47. Oruka Therapeutics has a 12-month low of $5.49 and a 12-month high of $42.88. The stock has a market capitalization of $1.93 billion, a price-to-earnings ratio of -20.92 and a beta of -0.38.

Oruka Therapeutics (NASDAQ:ORKA) last announced its quarterly earnings results on Thursday, March 12th. The company reported ($0.45) EPS for the quarter, topping the consensus estimate of ($0.61) by $0.16. Equities analysts forecast that Oruka Therapeutics will post -3.41 earnings per share for the current fiscal year.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.